Welcome to our dedicated page for Tango Therapeutics SEC filings (Ticker: TNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tango Therapeutics, Inc. filings document a clinical-stage precision oncology business and its Nasdaq-listed common stock. Current reports disclose operating and financial results, business highlights for vopimetostat and related development programs, material agreements, capital-raising arrangements such as at-the-market common stock sales, and updates to governance and executive leadership.
Proxy and compensation disclosures cover board matters, executive pay, pay-versus-performance data, equity awards, and shareholder voting matters. The company’s filings also address officer appointments and departures, separation and employment agreements, compensatory arrangements, capital structure, risk factors, and other material events affecting its biotechnology operations.
Tango Therapeutics announced several leadership changes and equity awards to support its late-stage oncology pipeline. The board decided that Daniella Beckman will step down as Chief Financial Officer, principal accounting officer and principal financial officer, effective April 15, 2026.
Effective the same date, Matthew Gall becomes Chief Financial Officer and principal financial officer under an employment agreement that includes an option for 240,000 shares and 40,000 restricted stock units, subject to time-based vesting and continued employment. Jessica Newcomb is appointed principal accounting officer, while a related press release highlights additional senior hires in development operations and corporate strategy to help advance vopimetostat toward potential regulatory approval in pancreatic cancer.
Tango Therapeutics President of R&D Crystal Adam exercised stock options for 27,000 shares of common stock at an exercise price of $5.20 per share and, on the same day, sold 27,000 shares at a weighted-average price of $21.2029 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. After the sale, Adam directly holds 112,622 shares of Tango Therapeutics common stock.
Tango Therapeutics, Inc. President of R&D Crystal Adam reported an option exercise and related stock sale. On March 25, 2026, she exercised stock options to acquire 12,000 shares of common stock at $5.20 per share, then sold 12,000 shares in open‑market transactions at a weighted‑average price of $20.11 per share.
These trades were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on October 27, 2025. After the transactions, she held 112,622 shares of common stock directly and 460,500 stock options, indicating the sale represents a relatively small portion of her overall position.
Tango Therapeutics received a Schedule 13G/A amendment from The Vanguard Group reporting 0 shares of Common Stock, representing 0% of the class. The filing states that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538; as a result, The Vanguard Group no longer reports beneficial ownership of those securities. The amendment is signed by Ashley Grim on March 27, 2026.
TNGX reports a proposed sale of 93,000 shares of Common Stock related to the exercise of stock options on 03/25/2026 for cash. The filing also lists prior Rule 10b5-1 sales by Adam Crystal, including 20,251, 54,345, and 18,452 shares on 03/05/2026, 02/25/2026, and 02/03/2026, respectively.
Tango Therapeutics, Inc. President of R&D Crystal Adam reported an open-market sale of 20,251 shares of common stock at $15.00 per share. After this transaction, she directly owned 112,622 shares of Tango Therapeutics common stock.
The sale was executed on March 5, 2026 and is described as an open-market or private transaction. According to a footnote, these trades were carried out under a pre-established Rule 10b5-1 trading plan adopted on October 27, 2025, which automates transactions under preset instructions.
Adam Crystal submitted a Form 144 reporting proposed dispositions of Common stock tied to option exercises and restricted stock units, and disclosing recent 10b5-1 sales. The filing lists an exercise of stock options for 15,000 shares on 03/05/2026 (cash), and restricted stock units totaling 5,251 with an award date of 02/03/2025.
The filing also reports completed 10b5-1 sales by Adam Crystal: 54,345 shares sold on 02/25/2026 for $694,208.46, and 18,452 shares sold on 02/03/2026 for $226,300.30.
Tango Therapeutics, Inc. reported fourth quarter and full-year 2025 results and provided pipeline and corporate updates. Cash, cash equivalents and marketable securities totaled $343.1 million as of December 31, 2025, which the company expects will fund operations into 2028.
Collaboration revenue was $62.4 million for 2025, up from $30.0 million in 2024, mainly reflecting recognition of remaining Gilead deferred revenue. Research and development expenses declined to $132.2 million from $143.9 million, while net loss narrowed to $101.6 million, or $0.87 per share, from $130.3 million, or $1.19 per share. The company highlighted progress for lead PRMT5 inhibitor vopimetostat, plans for a pivotal 2L pancreatic cancer study in 2026, new combination collaborations, and leadership changes including a new CEO and Chief Regulatory Officer.
Tango Therapeutics, Inc. files its 2025 annual report outlining an advanced pipeline of precision oncology programs built around synthetic lethality and biomarker-driven patient selection.
The company highlights vopimetostat (TNG462), a PRMT5 inhibitor for MTAP‑deleted cancers, with Phase 1/2 monotherapy data showing a 27% objective response rate and 6.4‑month median progression‑free survival across 94 evaluable patients, including 7.2‑month median progression‑free survival and 25% response rate in second‑line MTAP‑deleted pancreatic cancer. A histology‑selective cohort reported a 49% response rate and 9.1‑month median progression‑free survival. Combination trials with RAS(ON) inhibitors daraxonrasib and zoldonrasib are under way, along with a new collaboration with Erasca’s pan‑RAS agent ERAS‑0015.
TNG456, a brain‑penetrant PRMT5 inhibitor, is in a Phase 1/2 trial for MTAP‑deleted solid tumors with a focus on glioblastoma, supported by pharmacokinetics suggesting adequate central nervous system exposure; earlier candidate TNG908 was discontinued after subtherapeutic brain exposure. TNG961, an HBS1L degrader for FOCAD‑deleted/MTAP‑deleted tumors, remains in IND‑enabling development. CoREST inhibitor TNG260, combined with pembrolizumab, delivered a 29‑week median progression‑free survival in a five‑patient subgroup of checkpoint‑inhibitor‑resistant STK11‑mutant/KRAS wild‑type non‑small cell lung cancer, more than double the ~10‑week standard of care, and is continuing in that genetically defined cohort.
Tango Therapeutics, Inc. reported that Crystal Adam, its President, R&D, sold 54,345 shares of common stock on February 25, 2026. The open-market sale was executed at a weighted average price of $12.7741 per share under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025. Following this transaction, Adam directly owns 132,873 Tango Therapeutics common shares.